Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Open, Prospective, Randomized, Parallel-group, 24-month Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure

NCT06676696 is registered in ClinicalTrials.gov with Hospital Universitari Vall d'Hebron Research Institute as lead sponsor.

NCT NCT06676696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06676696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Open, Prospective, Randomized, Parallel-group, 24-month Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Phase
Phase 4
Overall status
Recruiting
Start date
January 22, 2024
Completion date
January 31, 2028
Enrollment
202 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allograft, graft failure, graft rejection, renal failure , chronic, renal failure chronic requiring dialysis